J0713 HCPCS Level II Code: Injection, ceftazidime, per 500 mg
Medicare Coverage & Payment
- CMS short descriptor: Inj ceftazidime per 500 mg
- Medicare coverage: Special coverage instructions apply (CMS coverage code D)
- Payment category: Drugs (pricing indicator 51)
- BETOS: O1E — Other drugs
- Last CMS action effective: January 1, 1997
Source: CMS HCPCS Level II release. Coverage codes indicate how Medicare treats the code, not whether a specific claim will be paid; payer policy and documentation still govern.
Change history
- January 1, 1996Added to the code setInjection, ceftazidime, per 500 mg
Drug products (NDC)
CMS ASP NDC-HCPCS Crosswalk · 2026 Q3
Medicare Part B payment limit (ASP + 6%): $1.44
00409-5082-16 Tazicef — Pfizer Inc (size 1 × qty 25 (500 MG per billing unit))
00409-5084-11 Tazicef — Pfizer Inc (size 1 × qty 10 (500 MG per billing unit))
00409-5086-11 Tazicef — Pfizer Inc (size 1 × qty 10 (500 MG per billing unit))
00409-5092-16 Tazicef — Pfizer Inc (size 1 × qty 25 (500 MG per billing unit))
00409-5093-11 Tazicef — Pfizer Inc (size 1 × qty 10 (500 MG per billing unit))
25021-0127-20 Ceftazidime — Sagent Pharmaceuticals (size 1 × qty 25 (500 MG per billing unit))
25021-0127-66 Ceftazidime — Sagent Pharmaceuticals (size 1 × qty 25 (500 MG per billing unit))
25021-0128-50 Ceftazidime — Sagent Pharmaceuticals (size 1 × qty 10 (500 MG per billing unit))
25021-0128-67 Ceftazidime — Sagent Pharmaceuticals (size 1 × qty 10 (500 MG per billing unit))
25021-0129-69 Ceftazidime — Sagent Pharmaceuticals (size 1 × qty 6 (500 MG per billing unit))
25021-0129-99 Ceftazidime — Sagent Pharmaceuticals (size 1 × qty 6 (500 MG per billing unit))
44567-0235-25 Ceftazidime — WG Critical Care, LLC (size 1 × qty 25 (500 MG per billing unit))
44567-0236-10 Ceftazidime — WG Critical Care, LLC (size 1 × qty 10 (500 MG per billing unit))
44567-0237-06 Ceftazidime — WG Critical Care, LLC (size 1 × qty 6 (500 MG per billing unit))
From the CMS ASP NDC-HCPCS Crosswalk and Part B Payment Limit File. Payment limits apply per HCPCS billing code, not per package.
Contextual Map
Every relationship of J0713 in one view: hierarchy, official tabular instructions in both directions, clinical classification, risk adjustment, MS-DRG participation, index terms and change history — each edge carrying the CMS source it derives from.
Nearest codes (34)
- J0701 — Injection, cefepime hydrochloride (baxter), not therapeutically equivalent to maxipime, 500 mg[Sibling]
- J0702 — Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg[Sibling]
- J0703 — Injection, cefepime hydrochloride (b braun), not therapeutically equivalent to maxipime, 500 mg[Sibling]
- J0706 — Injection, caffeine citrate, 5 mg[Sibling]
- J0710 — Injection, cephapirin sodium, up to 1 gm[Sibling]
- J0712 — Injection, ceftaroline fosamil, 10 mg[Sibling]
- J0714 — Injection, ceftazidime and avibactam, 0.5 g/0.125 g[Sibling]
- J0715 — Injection, ceftizoxime sodium, per 500 mg[Sibling]
- and 26 more
Change history
- January 1, 1996 — Added to the code set [Change history]
Nearest Codes in This Family
Official HCPCS Level II classifications closest to J0713 in its code family, with their registry titles.
- J0702 — Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg
- J0703 — Injection, cefepime hydrochloride (b braun), not therapeutically equivalent to maxipime, 500 mg
- J0706 — Injection, caffeine citrate, 5 mg
- J0710 — Injection, cephapirin sodium, up to 1 gm
- J0712 — Injection, ceftaroline fosamil, 10 mg
- J0714 — Injection, ceftazidime and avibactam, 0.5 g/0.125 g
- J0715 — Injection, ceftizoxime sodium, per 500 mg
- J0716 — Injection, centruroides immune f(ab)2, up to 120 milligrams
- J0717 — Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)
- J0720 — Injection, chloramphenicol sodium succinate, up to 1 gm